Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat

Citarinostat (ACY-241) is a promising oral histone deacetylase 6 (HDAC6)-selective inhibitor currently in clinical trials for the treatment of multiple myeloma (MM) and non-small-cell lung cancer (NSCLC). However, the inevitable emergence of resistance to citarinostat may reduce its clinical effecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chung-Pu, Hung, Cheng-Yu, Lusvarghi, Sabrina, Chang, Yen-Fu, Hsiao, Sung-Han, Huang, Yang-Hui, Hung, Tai-Ho, Yu, Jau-Song, Ambudkar, Suresh. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961520/
https://www.ncbi.nlm.nih.gov/pubmed/33807514
http://dx.doi.org/10.3390/ijms22052592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961520/
https://www.ncbi.nlm.nih.gov/pubmed/33807514
http://dx.doi.org/10.3390/ijms22052592

Ejemplares similares